Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-102 and SNS-103, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. The company was formerly known as Sensei Biotherapeutics, Inc. and changed its name to Faeth Therapeutics, Inc. in June 2026. The company was incorporated in 1999 and is headquartered in Rockville, Maryland.…
Faeth Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate PIKTOR in Combination with a Selective Estrogen Receptor Degrader in HR+/HER2- Advanced Breast Cancer
Faeth Therapeutics Reports Third Quarter 2026 Financial Results and Operational Updates
Faeth Therapeutics (NASDAQ: FTH) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 29 employees.
The shares were at 7.880 USD on 20 November 2026, down 13.4% over 52 weeks. Its 52-week range is 7.450 USD to 42.14 USD: the price is 81.3% below the high and 5.8% above the low.
Its market capitalisation is 203.65M USD.
Faeth Therapeutics reports return on equity of -113.4% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 174.65M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. The next earnings report is expected on 18 February 2027.